MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Country |
 Israel |
IPO year |
2013 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
27 M |
Market Cap[1] |
$ 225 M |
EBITDA (LTM) |
$ -56.6 M |
P/E (LTM) |
-4.73 |
P/S (LTM) |
1.61 |
EPS (LTM) |
-1.73 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Alector
ALEC
|
$ 2.08 | -14.4 % | $ 214 M | Nasdaq Global Select Market,SPB |  USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Altimmune
ALT
|
$ 4.2 | -2.67 % | $ 298 M | Nasdaq Global Market | USA |
 |
Apellis Pharmaceuticals
APLS
|
$ 20.24 | -3.44 % | $ 2.55 B | Nasdaq Global Select Market,SPB | USA |
 |
Aptorum Group Limited
APM
|
$ 0.8 | 1.87 % | $ 4.36 M | Nasdaq Global Select Market |  China |
 |
Aprea Therapeutics
APRE
|
$ 0.88 | -3.72 % | $ 3.18 M | Nasdaq Global Select Market,SPB | USA |
 |
Aptevo Therapeutics
APVO
|
$ 7.2 | -1.64 % | $ 1.99 M | Nasdaq Capital Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
Aquestive Therapeutics
AQST
|
$ 4.1 | 2.37 % | $ 356 M | Nasdaq Global Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Ardelyx
ARDX
|
$ 6.37 | -2.75 % | $ 1.54 B | Nasdaq Global Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
argenx SE
ARGX
|
$ 756.71 | -1.33 % | $ 25 B | Nasdaq Global Select Market |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
$ 10.91 | 1.58 % | $ 394 M | NYSE American | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 25.33 | -6.1 % | $ 3.22 B | Nasdaq Global Select Market,SPB | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Artelo Biosciences
ARTL
|
$ 1.15 | -3.36 % | $ 2.32 M | Nasdaq Global Select Market | USA |
 |
Arvinas
ARVN
|
$ 12.97 | -2.3 % | $ 920 M | Nasdaq Global Select Market,SPB | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 61.74 | -2.42 % | $ 8.26 B | Nasdaq Global Select Market,SPB | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 231.56 | -0.83 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.39 | -1.63 % | $ 8.16 B | Nasdaq Capital Market |  Australia |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.17 | -0.85 % | $ 35.2 M | NYSE American | USA |
 |
Atossa Therapeutics
ATOS
|
$ 4.39 | -0.9 % | $ 553 M | Nasdaq Capital Market | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 5.01 | -7.47 % | $ 37.5 M | Nasdaq Global Select Market,SPB | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 14.14 | -0.21 % | $ 1.9 B | Nasdaq Global Market |  Canada |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.68 | -1.75 % | $ 429 M | Nasdaq Global Select Market | Britain |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Atea Pharmaceuticals
AVIR
|
$ 4.69 | 0.21 % | $ 395 M | Nasdaq Global Select Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
$ 4.54 | 2.44 % | $ 387 M | Nasdaq Capital Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Axon Enterprise
AXON
|
$ 570.5 | 5.18 % | $ 43.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Axsome Therapeutics
AXSM
|
$ 162.28 | -0.98 % | $ 8.07 B | Nasdaq Global Market,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Aytu BioScience
AYTU
|
$ 2.56 | -0.58 % | $ 16.1 M | Nasdaq Capital Market | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.